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Summary The incidence rate of cutaneous lymphomas (CL) [including mycosisfungoides (MF) and non-mycosis fungoides (non-MF)] forthe
period 1985-93 in Israel was determined using data from the population-based Cancer Registry supplemented by a field survey that covered
approximately 80% of lymphoma cases. After the field survey, corrected rates were 49% and 24% higher for MF and non-MF respectively
(37% for CL overall). The age-adjusted incidence rates per 100 000 were 1.18 and 0.63 for Jewish men and women respectively. MF rates
(0.77 in men and 0.35 in women) were higher than non-MF (0.41 and 0.28 respectively). Rates of CL were significantly lower in non-Jews.
There were no significant differences in incidence among Jewish ethnic subgroups. However, the lack of variability in the incidence of these
neoplasms among subpopulations is in contrast with findings for cutaneous malignant melanoma; the observed high rates of CL could,
nonetheless, be consistent with the sunlight exposure hypothesis, operating perhaps through a different mechanism.
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International incidence data on cutaneous lymphoma (CL) from
population-based sources are sparce. These skin neoplasms encom-
pass a number of different entities, mostly but not exclusively
arising from malignant T lymphocytes (Burg et al, 1995). During
the last two decades there have been reports suggesting a rising
incidence of CL (Weinstock, 1994; Koh et al, 1995). Factors that
may have influenced reported rates ofCL include the introduction
ofmore sensitive methods ofdiagnosis (immunohistochemical and
molecular techniques, such as Southern blot analysis and poly-
merase chain reaction), more precise diagnostic criteria and an
increased public awareness ofthe need to seekearly medical atten-
tion for skin lesions. The risk of CL increases after immuno-
suppression, including congenital immunodeficiency syndromes,
exposure to immunosuppressive drugs and possibly after infection
with the human immunodeficiency virus (HIV) (Kantor et al, 1989;
Myskowski, 1991). Increased risk has also been postulated to be a
result ofdirect occupational exposures, but studies are inconsistent
in this regard (Tuyp et al, 1987; Whittemore et al, 1989).
On the basis of experimental and epidemiological evidence,
there have been suggestion that the worldwide increase in the inci-
dence of non-Hodgkin's lymphoma (NHL) (Devesa et al, 1992;
Coleman et al, 1993) might be caused by increased exposure to
sunlight (Kripke, 1990; IARC, 1992; Cartwright et al, 1994).
Some but not all studies suggest a positive temporal geographical
association of NHL with UV radiation (Benthan, 1996; Hartge et
al, 1996; McMichael et al, 1996; Freedman et al, 1997; Newton,
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1997). These inconsistent results are in contrast to the positive
association found between cutaneous malignant melanoma
(CMM) and non-melanoma skin cancers and solar exposure
(mainly UV radiation). If sunlight exposure is associated with
NHL, the effect should be particularly apparent for CL. The
Jewish population of European origin (mostly skin sensitivity
types I-IV; Fitzpatrick et al, 1974) experiences fourfold higher
incidence ofCMM compared with Jewish immigrants from Africa
and Asia and non-Jews (mainly skin type V) living in Israel
(Iscovich et al, 1995). Ifexposure to UV radiation is a factor in the
development of CL, a similar CMM-like pattern in CL incidence
would be expected in comparing these subpopulations.
We performed a nationwide survey of CL (including mycosis
fungoides (MF) and non-MF) to evaluate the notification process
and the accuracy ofreporting to the national cancerregistry and to
assess possible demographic and ethnic variations in the incidence
ofCL in Israel.
MATERIAL AND METHODS
For the present study, cases of CL for the period 1985-93 were
retrieved from the Israel Cancer Registry (ICR). The standard
methods of registration, including linkage with the Population
Register to obtain demographic data and country of origin, and a
review of the original medical documentation of each case are
described elsewhere (Steinitz et al, 1989). As CL is an uncommon
tumour, for which little experience has been accumulated in the
registration process, a wider retrieval base was examined in the
present study. This included other morphological entities under
which cases might have been misclassified (all malignant
lymphomas with uncertain localization and all with skin reoccur-
rence, all extranodal lymphomas and non-skin cancer without
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Table 1 Age-standarded incidence rates (ASR) of cutaneous lymphoma per 100 OOO, Israel,1985-93
Incidence from ICR' registered cases Incidence after completeness survey
Men Women Men Women
No.b ASRc 95% Cld No. ASR 95%CI No. ASR 95% Cl No. ASR 95% Cl
All cutaneous lymphomas
All Jews 156 0.83 0.69-0.96 94 0.47 0.37-0.57 219 1.18 1.02-1.34 124 0.63 0.51-0.79
Jews born in
Asia/Africa 39 0.68 0.46-0.90 16 0.27 0.13-0.41 56 0.97 0.71-1.23 22 0.63 0.51-0.79
Europe/America 83 0.9 0.66-1.14 57 0.65 0.44-0.86 115 1.23 0.96-1.5 70 0.75 0.52-0.98
Israel 34 1.17 0.64-1.70 21 0.73 0.34-1.12 48 1.43 0.86-2.00 32 1.16 0.67-1.65
Non-Jews 4 0.12 0.0-0.24 4 0.12 0.0-0.24 7 0.26 0.04-0.46 5 0.17 0.0-0.33
Mycosis fungoides
All Jews 95 0.49 0.39-0.59 50 0.25 0.18-0.32 147 0.77 0.64-0.90 69 0.35 0.26-0.44
Jews born in
Asia/Africa 28 0.48 0.30-0.66 9 0.16 0.05-0.27 39 0.66 0.45-0.87 12 0.21 0.09-0.33
Europe/America 52 0.53 0.35-0.71 32 0.37 0.22-0.52 80 0.82 0.60-1.04 39 0.44 0.27-0.61
Israel 15 0.44 0.11-0.77 9 0.27 0.04-0.50 28 0.70 0.40-1.00 18 0.61 0.26-0.96
Non-Jews 2 0.08 0.0-0.18 4 0.12 0.0-0.24 5 0.21 0.0-0.40 5 0.17 0.10-0.33
Non-mycosis fungoides
All Jews 61 0.34 0.20-0.48 44 0.22 0.13-0.31 72 0.41 0.25-0.56 55 0.28 0.10-0.46
Jews born in
Asia/Africa 11 0.20 0.08-0.32 7 0.09 0.0-0.31 17 0.31 0.06-0.56 10 0.15 0.02-0.28
Europe/America 31 0.37 0.20-0.54 25 0.28 0.17-0.39 35 0.41 0.25-0.57 31 0.31 0.20-0.42
Israel 19 0.73 0.20-1.26 12 0.46 0.34-0.58 20 0.73 0.20-1.26 14 0.55 0.23-0.87
Non-Jews 2 0.05 0.0-0.32 - - - 2 0.05 0.0-0.32 - -
alCR, Israel Cancer Regisry. bNo., Number of Cases. cASR, age-standardized incidence rate per 100 000. d95% Cl, 95% confidence interval.
histological confirmation - a total of 2482 cases). In addition, an
active re-abstracting procedure was undertaken to identify cases
that had not been previously notified to the ICR. This was carried
out in the six major hospitals that account for about 80% of
lymphoma diagnosis and treatment in Israel and involved a search
ofcase notes for an additional 928 subjects. The final file included
355 cases confirmed from the original file (n = 258), as well as
cases added from the uncertain appraisal group (n = 6) and from
the hospital survey (n = 96). Five cases were deemed to be false
positives because ofmiscoding. The corrected rate ofMF after all
the checks was 49% higher than the original ICR estimates for all
populations, whereas for non-MF the increase was 24%. The
majority ofadditional cases came from the pathology departments
ofthe six hospitals and from the outpatient departments (the latter
being outside the normal cancer registration process).
RESULTS
Table 1 provides the annual age-adjusted (world standard) inci-
dence rates per 100 000 for all CL, MF and non-MF by subpopula-
tions, before and after the completeness survey, using population
figures from the 1983 census and annual updates that are based on
accurate birth, death and immigration data published by the Israel
Central Bureau of Statistics.
The incidence ofCL for all Jews after the completeness survey
was 1.18 and 0.63 per 100 000 for men and women respectively.
Incidence rates of CL were higher in Israeli-born Jews and in
immigrants from Europe and America compared with those born
in Africa and Asia but the differences are not statistically signifi-
cant. The rates for CL in non-Jews were significantly lower than
those in Jews. However, at young ages (0-44 years), the rates per
100 000 were very similar in both Israeli-born Jews (0.26) and
non-Jews (0.22). The male to female ratio for CL was raised in the
Jewish population (1.87; 95% CI 1.24-2.50), particularly so for
MF (2.20; 95% CI 1.79 -2.61) compared with non-MF (1.46; 95%
CI 1.15-1.77), but not in the non-Jewish population.
The corrected incidence estimates of MF were 57% higher for
men and 40% higher for women compared with the original
CancerRegistry rates. In neither men nor women did the corrected
incidence vary substantially among subpopulations; the rates for
all Jews were 0.77 per 100 000 (95% CI 0.64-0.90) for men and
0.35 per 100 000 (95% CI 0.26-0.44) for women. The rates were
lower among non-Jews but significantly so only for men.
Corrected incidence rates ofnon-MF CL were 0.41 and 0.28 per
100 000 for Jewish men and women respectively. Israeli-born
Jews of both sexes experienced the highest rates and non-Jews
were less frequently afflicted, but differences in rates between
subpopulations were not statistically significant.
After case verification, the MF to non-MF ratio was 1.98
(226:129). Non-MF cases, grouped according to the Working
Formulation (NHL Pathological Classification Project, 1982) were
distributed as follows: intermediate-grade lymphomas, 45.7%
(n = 59); unspecified CL, 27.1% (n = 35); low-grade lymphomas,
14.7% (in which 13 out of 19 were follicular); peripheral T-cell
CL, 8.5% (n = 11); and high-grade lymphomas, 4.0% (n = 5).
DISCUSSION
This study has yielded three major findings. The first is substantial
under-reporting andunder-registration ofCL to the CancerRegistry.
In the revised figures, the coverage ofreported CL incidence should
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be almost complete. However, the rates may still be underestimated,
as an unknown number of affected persons may have been unaware
of the severity of their skin disease and therefore did not seek
medical advice (Chuang et al, 1990). The extent to which under-
reporting occurs in other population-based cancer registries is
unknown.
The second major finding of our study is the apparent high
incidence of CL among Jews in Israel. The ASR for CL, 0.9 per
100 000 (1.18 and 0.63 for men and women respectively) is high
compared with sparse data from other population-based studies.
Age-adjusted rates from the USA population of 0.3-0.5 per
100 000, which were published before our survey period from
selected areas of the USA (Young et al, 1981; Horn et al, 1984;
Weinstock et al, 1988), included geographical and racial variations
that were not clearly elucidated. The incidence of CL in the USA,
based on SEER data, rose from 0.19 per 100 000 in 1973 to 0.44 in
1984 (Weinstock and Horn, 1988) and may have continued to rise
(Weinstock, 1994; Koh et al, 1995). Mycosis fungoides data alone
are more readily available but, again, only for an earlier period.
Reports from the SEER registries for the 1970s and early 1980s
demonstrate twofold geographical and black-to-white variations
(rates adjusted to USA population per 100 000; in black0.52 and in
white 0.26) (Biggar et al, 1984; Horn et al, 1984), which compare
with the revised ASR fortheJewishpopulation in Israel of0.56 per
100 000 (0.77 for men and 0.35 for women). Incidence data
based on non-homogeneous registration processes from Australia
(Dougan et al, 1981), The Netherlands (Hamminga et al, 1980) and
Norway (McFadden et al, 1983) show an occurrence ranging
between 0.13 and 0.18 per 100 000. These international data thus
provide a problematic basis for comparison as reporting practices,
period and choice ofdenominators vary from study to study.
The third finding of our study, i.e. the lack of variability in the
incidence rates for CL by continent oforigin forJews and the indi-
cation that low rates among non-Jews may be due to under-
reporting among the elderly [as the rates at ages 0-44 years are
similar to those among Jews with the highestincidence rates (those
born in Israel)], is in contrast with the trends observed for CMM
(Iscovich et al, 1995). For CMM, fourfold differences in incidence
have been observed over the past 30 years in Israel between Jews
born in Israel or in the Americas or in Europe compared with those
born in Asia orAfrica and with non-Jews, which is consistent with
a gradient of risk operating on different skin phenotypes. Both
CMM and NHL have been postulated to be associated with expo-
sure to sunlight (Kripke, 1990; IARC, 1992; Cartwright et al,
1994), howeverthe findings ofourincidence study ofCL are diffi-
cult to reconcile with this hypothesis. Similarly, recent data from
the USA demonstrate no difference in rates between blacks and
whites, nor an increased incidence for white Americans associated
with average daily dose of UV irradiation (Newton, 1997). One
tenable hypothesis is that at an individual level there may be
important differences in the types or extent of exposure that are
critical for the development of each particular cancer. For
example, episodic exposure to UV in childhood is probably
important for an increase of lifetime risk of malignant melanoma
(Kricker et al, 1993), whereas cumulative exposure to UV in mid-
life may be important for NHL, including CL.
The mechanism of tumorigenesis of these neoplasms may also
differ. For example, there is biological evidence for systemic
suppression ofcell-mediated immunity by UV in both humans and
animals (Morrison, 1989; Kripke, 1994). McMichael and Giles
(1996) recently reported evidence in both humans and animals
suggesting that ultraviolet (in particular UV-B ranging from 280 to
320 nm) irradiation of the skin at quite modest levels can cause
local and, probably, systemic suppression of immune function.
One hypothesis is that an increase in exposure to UV-B irradiation
could possibly increase the incidence of NHL by inducing some
degree of immunosuppression that is not necessarily associated
with skin pigmentation (McMichael et al, 1996). As skin pigmen-
tation does not lessen the degree ofUV-B penetration (Vermeer et
al, 1991), it would be expected that CL incidence rates would not
vary among populations with different grades ofskin pigmentation
within a defined geographical area. Altematively, the lack of
statistically significant differences in CL rates by continent ofbirth
subgroups and the lack of an association with UV light in the
recent American data (Newton, 1997) may suggest that these
tumours are not caused by excessive sunlight exposure, despite the
high incidence reported in Israel.
In summary, a study ofCL incidence was carried out using data
from multiple sources, based on a defined geographical area with
high sunlight exposure. We conclude that CL is apparently more
common in Israel than in other countries with available data, but
that there is no significant Jewish ethnic variation. Further investi-
gation will be required to confirm whether the high rates for CL
are as the result ofreporting practices or reflect a true difference in
incidence rates. If the latter is the case, aetiological factors,
including exposure to sunlight and skin phenotypes, will need to
be carefully explored.
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